First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 2, 2013, Pages 163-169

  Abila, B ^a   Cunningham, E ^b   Simeoni, M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P INHIBITOR; GSK 249320; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEPHAROSPASM; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DERMATITIS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPISTAXIS; EXCORIATION; FEMALE; FLATULENCE; GASTROENTERITIS; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERHIDROSIS; IMMUNOGENICITY; LUNG CONGESTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; MUSCLE STRAIN; MYALGIA; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NORMAL HUMAN; NOSE OBSTRUCTION; OROPHARYNX PAIN; PARALLEL DESIGN; PERIPHERAL NEUROPATHY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SENSORY ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN MANIFESTATION; SOMNOLENCE; STEADY STATE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURAL CONDUCTION; SENSORY THRESHOLDS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84872683666     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.227     Document Type: Article

References (24)

1. Mackay J. & Mensah G. The Atlas of Heart Disease and Stroke. (World Health Organization, Geneva, Switzerland, 2004).
2. Adamson, J., Beswick, A. & Ebrahim, S. Is stroke the most common cause of disability? J. Stroke Cerebrovasc. Dis. 13, 171-177 (2004).
3. The National Institute of Neurological Diseases and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. New Engl. J. Med. 333, 1581-1587 (1995).
4. Adeoye, O., Hornung, R., Khatri, P. & Kleindorfer, D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 42, 1952-1955 (2011).
5. Goldstein, L.B. Acute ischemic stroke treatment in 2007. Circulation 116, 1504-1514 (2007).
6. Good, D.C., Bettermann, K. & Reichwein, R.K. Stroke rehabilitation. Continuum (Minneap. Minn). 17, 545-567 (2011).
7. Cramer, S.C. Repairing the human brain after stroke. II. Restorative therapies. Ann. Neurol. 63, 549-560 (2008).
8. Llorens, F., Gil, V. & del Río, J.A. Emerging functions of myelin-associated proteins during development, neuronal plasticity, and neurodegeneration. FASEB J. 25, 463-475 (2011).
9. Li, S. & Carmichael, S.T. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. Neurobiol. Dis. 23, 362-373 (2006).
10. Guadagno, J.V. et al. Selective neuronal loss in rescued penumbra relates to initial hypoperfusion. Brain 131, 2666-2678 (2008).
11. Irving, E.A. et al. Identifcation of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? J. Cereb. Blood Flow Metab. 25, 98-107 (2005).
12. Mears, S., Schachner, M. & Brushart, T.M. Antibodies to myelin-associated glycoprotein accelerate preferential motor reinnervation. J. Peripher. Nerv. Syst. 8, 91-99 (2003).
13. Nobile-Orazio, E. et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann. Neurol. 26, 543-550 (1989).
14. Kyle, R.A. & Rajkumar, S.V. Monoclonal gammopathy of undetermined signifcance and smoldering multiple myeloma. Hematol. Oncol. Clin. North Am. 21, 1093-113, ix (2007).
15. Berger, T. et al. Antimyelin antibodies as a predictor of clinically defnite multiple sclerosis after a frst demyelinating event. N. Engl. J. Med. 349, 139-145 (2003).
16. Tomassini, V. et al. Anti-myelin antibodies predict the clinical outcome after a frst episode suggestive of MS. Mult. Scler. 13, 1086-1094 (2007).
17. Mattila, O.S. et al. Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke 42, 3600-3605 (2011).
18. Liu, J., Jin, X., Liu, K.J. & Liu, W. Matrix metalloproteinase-2- mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J. Neurosci. 32, 3044-3057 (2012).
19. Thompson, H.J. et al. Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody. Eur. J. Neurosci. 24, 3063-3072 (2006).
20. Agoram, B.M., Martin, S.W. & van der Graaf, P.H. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov. Today 12, 1018-1024 (2007).
21. Tang, L., Persky, A.M., Hochhaus, G. & Meibohm, B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93, 2184-2204 (2004).
22. Mascelli, M.A. et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J. Clin. Pharmacol. 47, 553-565 (2007).
23. Retzlaf, J.A., Tauxe, W.N., Kiely, J.M. & Stroebel, C.F. Erythrocyte volume, plasma volume, and lean body mass in adult men and women. Blood 33, 649-661 (1969).
24. Cornblath, D.R. et al. Total neuropathy score: validation and reliability study. Neurology 53, 1660-1664 (1999).